menu ☰
menu ˟

ThromboGenics enters into exclusive licensing agreement with Galapagos

18 Mar 2016
ThromboGenics has signed an exclusive licensing agreement with Galapagos to develop and commercialize integrin antagonists to treat diabetic eye disease, according to a press release. ThromboGenics will pay a 1 million upfront technology transfer pay...

Click here to view the full article which appeared in Optometry

IPH Logo